Bradbury Group has committed to a US$20 million strategic investment in Mirror Biologics, Inc. The allocation successfully closes out the issuer’s US$30 million Series A funding round. Capital is directed toward the advancement of clinical trials and the expansion of proprietary biomanufacturing capabilities.
In October 2022, Bradbury Group finalized a US$20 million investment in Mirror Biologics, Inc., an international clinical-stage biotechnology company. This capital injection marks the final close of the issuer’s US$30 million Series A private equity round.
The funding is allocated to support Mirror Biologics’ clinical pipeline, specifically advancing its ongoing immunology and oncology clinical trials. Additionally, proceeds from the Series A round are directed toward the expansion of the company’s commercial-scale biomanufacturing infrastructure and general corporate working capital. This transaction aligns with Bradbury’s strategic mandate of deploying capital into regulated, mid-to-late-stage life science and biopharma enterprises.
Capital from this placement is explicitly directed toward the advancement of the issuer’s clinical research pipeline. This includes providing funding for the ongoing investigational trials of IGC-AD1, a therapeutic candidate targeting agitation in Alzheimer’s disease, alongside standard corporate working capital. The transaction reflects Bradbury’s continued deployment of capital into regulated, clinical-stage life science mandates.
